Clinical Trials Logo

Reactive Arthritis clinical trials

View clinical trials related to Reactive Arthritis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04751396 Recruiting - Clinical trials for Rheumatoid Arthritis

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

Start date: April 20, 2022
Phase:
Study type: Observational

This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of the tool. Researchers will use the information collected to improve the educational materials that will help patients make future decisions about their treatment.

NCT ID: NCT04402086 Recruiting - Clinical trials for Rheumatoid Arthritis

Rheumatology Patient Registry and Biorepository

Start date: August 4, 2020
Phase:
Study type: Observational [Patient Registry]

To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.

NCT ID: NCT00244179 Recruiting - Reactive Arthritis Clinical Trials

New Immunomodulatory Therapy Strategies in Chronic Reactive Arthritis

Start date: January 2003
Phase: Phase 2
Study type: Interventional

1. to investigate, whether one of the two alternative therapy strategies (antibiotic plus immunostimulation versus antibiotic plus immunosuppression) in chronic reactive arthritis is therapeutical superior to conventionel standardtherapy (DMARD). 2. to investigate, whether one or more of the different therapy strategies cause an altered detection of bacterial DNA in the joint or colon. 3. to measure the antigen-specific and -unspecific immune response (predominantly t-cell response) during therapy and correlate it with the clinical course. 4. to gain knowledge from these analyses and the clinical course concerning the pathogenesis and the point of attack for possible therapies in chronic reactive arthritis. 5. to compare cytokine-profiles of CD4- and CD8-positive T-cells from patients treated with infliximab to those treated with etanercept.